重组人干扰素α1b治疗小儿手足口病的临床疗效观察(1)
摘要：目的 观察重组人干扰素α1b治疗小儿手足口病的临床疗效。方法 选择我院2018年6月～8月儿科门诊收治的手足口病患儿60例，随机分为治疗组和对照组，各30例。对照组患儿给予一般抗病毒对症治疗，治疗组在此基础上加用重组人干扰素α1b注射液治疗。观察两组患儿治疗后热退时间、咽部充血程度改善时间、口腔溃疡愈合时间及皮疹消退时间，比较两组患儿的临床疗效。结果 治疗组总有效率为93.33%，高于对照组的70.00%，差异有统计学意义(P<0.05);治疗组的热退时间、咽峡部充血程度改善时间、口腔溃疡愈合时间及皮疹消退时间均短于对照组，差异有统计学意义(P<0.05)。结论 重组人干扰素α1b注射液治疗小儿手足口病疗效确切，可有效加快患者临床症状改善，缩短患儿病程。
关键词：重组人干扰素α1b;手足口病;皮疹
中图分类号：R725.1 文獻标识码：A DOI：10.3969/j.issn.1006-1959.2019.05.050
, http://www.100md.com
文章编号：1006-1959(2019)05-0156-02
Abstract：Objective To observe the clinical efficacy of recombinant human interferon α1b in the treatment of hand， foot and mouth disease in children.Methods 60 children with hand， foot and mouth disease admitted to our hospital from June to August 2018 were randomly divided into treatment group and control group， 30 cases each. The control group received general antiviral symptomatic treatment， and the treatment group was treated with recombinant human interferon α1b injection. The postoperative heat withdrawal time， the improvement time of pharyngeal congestion， the time of oral ulcer healing and the time of rash regression were observed in the two groups. The clinical effects of the two groups were compared. Results The total effective rate of the treatment group was 93.33%， which was higher than that of the control group 70.00%，the difference was statistically significant (P<0.05). The heat withdrawal time， the time of improvement of pharyngeal congestion， the healing time of oral ulcer and the rash subsided in the treatment group. The time was shorter than the control group，the difference was statistically significant (P<0.05).Conclusion Recombinant human interferon α1b injection is effective in the treatment of hand， foot and mouth disease in children， which can effectively improve the clinical symptoms of patients and shorten the course of children.
, 百拇医药
Key words：Recombinant human interferon α1b;Hand，foot and mouth disease;Rash
手足口病(hand-foot-mouth disease)是由肠道病毒所致的儿童期急性传染病，常见于5岁以下儿童，夏秋季多见，以手、足部出疹和口腔粘膜疱疹或溃疡为特征性表现，绝大部分患儿在发病后5～7 d后自行缓解，少部分患儿发展为重症，通常在发病后1～4 d出现中枢神经系统受累等并发症，危重症病例进展迅速，如不及早诊断和救治则病死率超过80%[1]。病原学主要为柯萨奇病毒A组16型(CoxA16)和肠道病毒71型(enterovirus 71，EV71)，其他肠道病毒如柯萨奇病毒A5、A7、A9、A10以及柯萨奇病毒B2、B5也可引致[2]。目前临床对普通型手足口病的治疗主要为对症治疗，我院儿科门诊应用运德素(重组人干扰素α1b注射液)治疗小儿手足口病，对于缩短病程疗效确切，现报道如下。, http://www.100md.com(李正兰)
关键词：重组人干扰素α1b;手足口病;皮疹
中图分类号：R725.1 文獻标识码：A DOI：10.3969/j.issn.1006-1959.2019.05.050
, http://www.100md.com
文章编号：1006-1959(2019)05-0156-02
Abstract：Objective To observe the clinical efficacy of recombinant human interferon α1b in the treatment of hand， foot and mouth disease in children.Methods 60 children with hand， foot and mouth disease admitted to our hospital from June to August 2018 were randomly divided into treatment group and control group， 30 cases each. The control group received general antiviral symptomatic treatment， and the treatment group was treated with recombinant human interferon α1b injection. The postoperative heat withdrawal time， the improvement time of pharyngeal congestion， the time of oral ulcer healing and the time of rash regression were observed in the two groups. The clinical effects of the two groups were compared. Results The total effective rate of the treatment group was 93.33%， which was higher than that of the control group 70.00%，the difference was statistically significant (P<0.05). The heat withdrawal time， the time of improvement of pharyngeal congestion， the healing time of oral ulcer and the rash subsided in the treatment group. The time was shorter than the control group，the difference was statistically significant (P<0.05).Conclusion Recombinant human interferon α1b injection is effective in the treatment of hand， foot and mouth disease in children， which can effectively improve the clinical symptoms of patients and shorten the course of children.
, 百拇医药
Key words：Recombinant human interferon α1b;Hand，foot and mouth disease;Rash
手足口病(hand-foot-mouth disease)是由肠道病毒所致的儿童期急性传染病，常见于5岁以下儿童，夏秋季多见，以手、足部出疹和口腔粘膜疱疹或溃疡为特征性表现，绝大部分患儿在发病后5～7 d后自行缓解，少部分患儿发展为重症，通常在发病后1～4 d出现中枢神经系统受累等并发症，危重症病例进展迅速，如不及早诊断和救治则病死率超过80%[1]。病原学主要为柯萨奇病毒A组16型(CoxA16)和肠道病毒71型(enterovirus 71，EV71)，其他肠道病毒如柯萨奇病毒A5、A7、A9、A10以及柯萨奇病毒B2、B5也可引致[2]。目前临床对普通型手足口病的治疗主要为对症治疗，我院儿科门诊应用运德素(重组人干扰素α1b注射液)治疗小儿手足口病，对于缩短病程疗效确切，现报道如下。, http://www.100md.com(李正兰)